Altered kynurenine pathway metabolism in autism: Implication for immune-induced glutamatergic activity

Autism Research

Volumn 9, Issue 6, 2016, Pages 621-631

  Lim, Chai K ^a   Essa, Musthafa M ^b   de Paula Martins, Roberta ^a   Lovejoy, David B ^a   Bilgin, Ayse A ^a   Waly, Mostafa I ^b   Al Farsi, Yahya M ^b   Al Sharbati, Marwan ^b   Al Shaffae, Mohammed A ^b   Guillemin, Gilles J ^a  

^a MACQUARIE UNIVERSITY   (Australia)

^b SULTAN QABOOS UNIVERSITY   (Oman)

Author keywords

autism; excitotoxicity; glutamatergic activity; kynurenine pathway; neuroinflammation; quinolinic acid

Indexed keywords

GAMMA INTERFERON; GAMMA INTERFERON INDUCIBLE PROTEIN 10; INTERLEUKIN 1 RECEPTOR; INTERLEUKIN 10; INTERLEUKIN 17; INTERLEUKIN 6; KYNURENINE; MACROPHAGE INFLAMMATORY PROTEIN 1BETA; NEOPTERIN; QUINOLINIC ACID; TUMOR NECROSIS FACTOR ALPHA;

ADAPTIVE IMMUNITY; AMINO ACID METABOLISM; ARTICLE; AUTISM; CHILD; CONTROLLED STUDY; CROSS-SECTIONAL STUDY; CYTOKINE PRODUCTION; EXCITOTOXICITY; FEMALE; HUMAN; IMMUNE RESPONSE; INNATE IMMUNITY; MACROPHAGE; MALE; NEUROPROTECTION; NEUROTRANSMISSION; PATHOGENESIS; PRIORITY JOURNAL; PROTEIN EXPRESSION; SCHOOL CHILD; SEROTONIN METABOLISM; SIBLING; UPREGULATION;

EID: 84974784672     PISSN: 19393792     EISSN: 19393806     Source Type: Journal    
DOI: 10.1002/aur.1565     Document Type: Article

References (65)

1. Al-Ayadhi, L., & Mostafa, G. (2012). Elevated serum levels of interleukin-17A in children with autism. Journal of Neuroinflammation, 9, 158.
2. Beninger, R.J., Colton, A.M., Ingles, J.L., Jhamandas, K., & Boegman, R.J. (1994). Picolinic acid blocks the neurotoxic but not the neuroexcitant properties of quinolinic acid in the rat brain: Evidence from turning behaviour and tyrosine hydroxylase immunohistochemistry. Neuroscience, 61, 603–612.
3. Boccuto, L., Chen, C.-F., Pittman, A., Skinner, C., McCartney, H., Jones, K., et al. (2013). Decreased tryptophan metabolism in patients with autism spectrum disorders. Molecular Autism, 4, 16.
4. Braidy, N., Grant, R., Adams, S., Brew, B.J., & Guillemin, G.J. (2009). Mechanism for quinolinic acid cytotoxicity in human astrocytes and neurons. Neurotox Research, 16, 77–86.
5. Brown, M.S., Singel, D., Hepburn, S., & Rojas, D.C. (2013). Increased glutamate concentration in the auditory cortex of persons with autism and first-degree relatives: A (1)H-MRS study. Autism Research: Official Journal of the International Society for Autism Research, 6, 1–10.
6. Curzon, G. (1979). Relationships between plasma, CSF and brain tryptophan. In P. Baumann (Ed.), Transport mechanisms of tryptophan in blood cells, nerve cells, and at the blood-brain barrier (Vol. 15). Vienna: Springer.
7. Danielsson, S., Gillberg, I.C., Billstedt, E., Gillberg, C., & Olsson, I. (2005). Epilepsy in young adults with autism: A prospective population-based follow-up study of 120 individuals diagnosed in childhood. Epilepsia, 46, 918–923.
8. Dantzer, R., O'Connor, J.C., Lawson, M.A., & Kelley, K.W. (2010). Inflammation-associated depression: From serotonin to kynurenine. Psychoneuroendocrinology, 36, 426–436.
9. De Bildt, A., Sytema, S., Ketelaars, C., Kraijer, D., Mulder, E., Volkmar, F., et al. (2004). Interrelationship between autism diagnostic observation schedule-generic (ADOS-G), autism diagnostic interview-revised (ADI-R), and the diagnostic and statistical manual of mental disorders (DSM-IV-TR) classification in children and adolescents with mental retardation. Journal of Autism Dev Disord, 34, 129–137.
10. De Oliveira, D.L., Horn, J.F., Rodrigues, J.M., Frizzo, M.E., Moriguchi, E., Souza, D.O., et al. (2004). Quinolinic acid promotes seizures and decreases glutamate uptake in young rats: Reversal by orally administered guanosine. Brain Research, 1018, 48–54.
11. DeLong, G.R. (1999). Autism: New data suggest a new hypothesis. Neurology, 52, 911–916.
12. Deykin, E.Y., & MacMahon, B. (1979). The incidence of seizures among children with autistic symptoms. American Journal of Psychiatry, 136, 1310–1312.
13. Erhardt, S., Lim, C.K., Linderholm, K.R., Janelidze, S., Lindqvist, D., Samuelsson, M., et al. (2013). Connecting inflammation with glutamate agonism in suicidality. Neuropsychopharmacology, 38, 743–752.
14. Essa, M.M., Braidy, N., Waly, M.I., Al-Farsi, Y.M., Al-Sharbati, M., Subash, S., et al. (2013). Impaired antioxidant status and reduced energy metabolism in autistic children. Research in Autism Spectrum Disorders, 7, 557–565.
15. Folsom, T., & Fatemi, S.H. (2011). Neurochemistry of autism. In J.P. Blass (Ed.), Neurochemical mechanisms in disease (Vol. 1). New York: Springer. pp. 383–398.
16. Ghaleiha, A., Asadabadi, M., Mohammadi, M.R., Shahei, M., Tabrizi, M., Hajiaghaee, R., et al. (2013). Memantine as adjunctive treatment to risperidone in children with autistic disorder: A randomized, double-blind, placebo-controlled trial. The International Journal of Neuropsychopharmacology/Official Scientific Journal of the Collegium Internationale Neuropsychopharmacologicum (CINP), 16, 783–789.
17. Guillemin, G.J. (2012). Quinolinic acid, the inescapable neurotoxin. FEBS J, 279, 1356–1365.
18. Guillemin, G.J., Cullen, K.M., Lim, C.K., Smythe, G.A., Garner, B., Kapoor, V., et al. (2007). Characterization of the kynurenine pathway in human neurons. Journal of Neurosci, 27, 12884–12892.
19. Guillemin, G.J., Kerr, S.J., Pemberton, L.A., Smith, D.G., Smythe, G.A., Armati, P.J., et al. (2001). IFN-beta1b induces kynurenine pathway metabolism in human macrophages: Potential implications for multiple sclerosis treatment. Journal of Interferon & Cytokine Research, 21, 1097–1101.
20. Guillemin, G.J., Smythe, G., Takikawa, O., & Brew, B.J. (2005). Expression of indoleamine 2,3-dioxygenase and production of quinolinic acid by human microglia, astrocytes, and neurons. Glia, 49, 15–23.
21. Horev, G., Ellegood, J., Lerch, J.P., Son, Y.-E.E., Muthuswamy, L., Vogel, H., et al. (2011). Dosage-dependent phenotypes in models of 16p11.2 lesions found in autism. Proceedings of the National Academy of Sciences, 108, 17076–17081.
22. Huber, C., Batchelor, J.R., Fuchs, D., Hausen, A., Lang, A., Niederwieser, D., et al. (1984). Immune response-associated production of neopterin. Release from macrophages primarily under control of interferon-gamma. The Journal of Experimental Medicine, 160, 310–316.
23. Jyonouchi, H., Sun, S., & Le, H. (2001). Proinflammatory and regulatory cytokine production associated with innate and adaptive immune responses in children with autism spectrum disorders and developmental regression. Journal of Neuroimmunology, 120, 170–179.
24. Kalisch, B.E., Jhamandas, K., Boegman, R.J., & Beninger, R.J. (1994). Picolinic acid protects against quinolinic acid-induced depletion of NADPH diaphorase containing neurons in the rat striatum. Brain Research, 668, 1–8.
25. Khan, A. (2012). Detection and quantitation of forty eight cytokines, chemokines, growth factors and nine acute phase proteins in healthy human plasma, saliva and urine. Journal of Proteomics, 75, 4802–4819.
26. Kumar, R.A., KaraMohamed, S., Sudi, J., Conrad, D.F., Brune, C., Badner, J.A., et al. (2008). Recurrent 16p11.2 microdeletions in autism. Human Molecular Genetics, 17, 628–638.
27. Li, X., Chauhan, A., Sheikh, A.M., Patil, S., Chauhan, V., Li, X.-M., et al. (2009). Elevated immune response in the brain of autistic patients. Journal of Neuroimmunology, 207, 111–116.
28. Liebau, C., Baltzer, A.W., Schmidt, S., Roesel, C., Karreman, C., Prisack, J.B., et al. (2002). Interleukin-12 and interleukin-18 induce indoleamine 2,3-dioxygenase (IDO) activity in human osteosarcoma cell lines independently from interferon-gamma. Anticancer Research, 22, 931–936.
29. Lim, C.K., Yap, M.M.C., Kent, S.J., Gras, G., Samah, B., Batten, J.C., et al. (2013). Characterization of the kynurenine pathway and quinolinic acid production in macaque macrophages. International Journal of Tryptophan Research, 6, 7–19.
30. Makkonen, I., Riikonen, R., Kokki, H., Airaksinen, M.M., & Kuikka, J.T. (2008). Serotonin and dopamine transporter binding in children with autism determined by SPECT. Developmental Medicine and Child Neurology, 50, 593–597.
31. McDougle, C.J., Naylor, S.T., Cohen, D.J., Aghajanian, G.K., Heninger, G.R., & Price, L.H. (1996). Effects of tryptophan depletion in drug-free adults with autistic disorder. Archives of General Psychiatry, 53, 993–1000.
32. Meyer, U., Feldon, J., & Dammann, O. (2011). Schizophrenia and autism: Both shared and disorder-specific pathogenesis via perinatal inflammation? Pediatric Research, 69, 26R–33R.
33. Munn, D.H., Zhou, M., Attwood, J.T., Bondarev, I., Conway, S.J., Marshall, B., et al. (1998). Prevention of allogeneic fetal rejection by tryptophan catabolism. Science, 281, 1191–1193.
34. O'Connor, J.C., André, C., Wang, Y., Lawson, M.A., Szegedi, S.S., Lestage, J., et al. (2009). Interferon-γ and tumor necrosis factor-α mediate the upregulation of indoleamine 2,3-dioxygenase and the induction of depressive-like behavior in mice in response to bacillus calmette-guérin. The Journal of Neuroscience, 29, 4200–4209.
35. Oades, R.D., Dauvermann, M.R., Schimmelmann, B.G., Schwarz, M.J., & Myint, A.M. (2010). Attention-deficit hyperactivity disorder (ADHD) and glial integrity: S100B, cytokines and kynurenine metabolism—Effects of medication. Behavioral and Brain Functions, 6, 29.
36. Olsson, S.K., Samuelsson, M., Saetre, P., Lindstrom, L., Jonsson, E.G., Nordin, C., et al. (2010). Elevated levels of kynurenic acid in the cerebrospinal fluid of patients with bipolar disorder. Journal of Psychiatry Neuroscience, 35, 195–199.
37. Pemberton, L.A., Kerr, S.J., Smythe, G., & Brew, B.J. (1997). Quinolinic acid production by macrophages stimulated with IFN-gamma, TNF-alpha, and IFN-alpha. Journal of Interferon & Cytokine Research, 17, 589–595.
38. Petersen, A.M., & Pedersen, B.K. (2005). The anti-inflammatory effect of exercise. Journal of Applied Physiology (Bethesda, MD: 1985), 98, 1154–1162.
39. Raison, C.L., Dantzer, R., Kelley, K.W., Lawson, M.A., Woolwine, B.J., Vogt, G., et al. (2010). CSF concentrations of brain tryptophan and kynurenines during immune stimulation with IFN-alpha: Relationship to CNS immune responses and depression. Molecular Psychiatry, 15, 393–403.
40. Rosenhall, U., Nordin, V., Sandström, M., Ahlsén, G., & Gillberg, C. (1999). Autism and hearing loss. Journal of Autism and Developmental Disorders, 29, 349–357.
41. Rubenstein, J.L., & Merzenich, M.M. (2003). Model of autism: Increased ratio of excitation/inhibition in key neural systems. Genes, Brain, and Behavior, 2, 255–267.
42. Santana-Martinez, R.A., Galvan-Arzate, S., Hernandez-Pando, R., Chanez-Cardenas, M.E., Avila-Chavez, E., Lopez-Acosta, G., et al. 2014. Sulforaphane reduces the alterations induced by quinolinic acid: Modulation of glutathione levels. Neuroscience, 272, 188–198.
43. Schwarcz, R., Brush, G.S., Foster, A.C., & French, E.D. (1984). Seizure activity and lesions after intrahippocampal quinolinic acid injection. Experimental Neurology, 84, 1–17.
44. Singh, K., Connors, S.L., Macklin, E.A., Smith, K.D., Fahey, J.W., Talalay, P., et al. (2014). Sulforaphane treatment of autism spectrum disorder (ASD). Proceedings of the National Academy of Sciences, 111, 15550–15555.
45. Smythe, G.A., Braga, O., Brew, B.J., Grant, R.S., Guillemin, G.J., Kerr, S.J., et al. (2002). Concurrent quantification of quinolinic, picolinic, and nicotinic acids using electron-capture negative-ion gas chromatography-mass spectrometry. Analytical Biochemistry, 301, 21–26.
46. Steiner, J., Walter, M., Gos, T., Guillemin, G., Bernstein, H.-G., Sarnyai, Z., et al. (2011). Severe depression is associated with increased microglial quinolinic acid in subregions of the anterior cingulate gyrus: Evidence for an immune-modulated glutamatergic neurotransmission? Journal of Neuroinflammation, 8, 94.
47. Stone, T.W. (1993). Neuropharmacology of quinolinic and kynurenic acids. Pharmacological Reviews, 45, 309–379.
48. Stone, T.W., & Perkins, M.N. (1981). Quinolinic acid: A potent endogenous excitant at amino acid receptors in CNS. European Journal of Pharmacology, 72, 411–412.
49. Sublette, M.E., Galfalvy, H.C., Fuchs, D., Lapidus, M., Grunebaum, M.F., Oquendo, M.A., et al. (2011). Plasma kynurenine levels are elevated in suicide attempters with major depressive disorder. Brain, Behavior, and Immunity, 25, 1272–1278.
50. Suzuki, K., Matsuzaki, H., Iwata, K., Kameno, Y., Shimmura, C., Kawai, S., et al. (2011). Plasma cytokine profiles in subjects with high-functioning autism spectrum disorders. PLoS One, 6, e20470.
51. Sweeten, T.L., Posey, D.J., & McDougle, C.J. (2003). High blood monocyte counts and neopterin levels in children with autistic disorder. American Journal of Psychiatry, 160, 1691–1693.
52. Sweeten, T.L., Posey, D.J., Shankar, S., & McDougle, C.J. (2004). High nitric oxide production in autistic disorder: A possible role for interferon-gamma. Biological Psychiatry, 55, 434–437.
53. Sweeten, T., Taylor, M., Posey, D., & McDougle, C. (2006). Plasma kynurenine levels in autistic disorder. Journal of Developmental and Physical Disabilities, 18, 419–426.
54. Tavares, R.G., Tasca, C.I., Santos, C.E., Alves, L.B., Porciuncula, L.O., Emanuelli, T., et al. (2002). Quinolinic acid stimulates synaptosomal glutamate release and inhibits glutamate uptake into astrocytes. Neurochemistry International, 40, 621–627.
55. Tavares, R.G., Tasca, C.I., Santos, C.E., Wajner, M., Souza, D.O., & Dutra-Filho, C.S. (2000). Quinolinic acid inhibits glutamate uptake into synaptic vesicles from rat brain. Neuroreport, 11, 249–253.
56. Tebartz van Elst, L., Maier, S., Fangmeier, T., Endres, D., Mueller, G.T., Nickel, K., et al. (2014). Disturbed cingulate glutamate metabolism in adults with high-functioning autism spectrum disorder: Evidence in support of the excitatory/inhibitory imbalance hypothesis. Molecular Psychiatry, 19, 1314–1325.
57. Ting, K.K., Brew, B.J., & Guillemin, G.J. (2009). Effect of quinolinic acid on human astrocytes morphology and functions: Implications in Alzheimer's disease. Journal of Neuroinflammation, 6, 36.
58. Vargas, D.L., Nascimbene, C., Krishnan, C., Zimmerman, A.W., & Pardo, C.A. (2005). Neuroglial activation and neuroinflammation in the brain of patients with autism. Annals of Neurology, 57, 67–81.
59. Weiss, L.A., Shen, Y., Korn, J.M., Arking, D.E., Miller, D.T., Fossdal, R., et al. (2008). Association between microdeletion and microduplication at 16p11.2 and autism. New England Journal of Medicine, 358, 667–675.
60. Wonodi, I., Stine, O.C., Sathyasaikumar, K.V., Roberts, R.C., Mitchell, B.D., Hong, L.E., et al. (2011). Downregulated kynurenine 3-monooxygenase gene expression and enzyme activity in schizophrenia and genetic association with schizophrenia endophenotypes. Archives of General Psychiatry, 68, 665–674.
61. Yellon, R.F., Rose, E., Kenna, M.A., Doyle, W.J., Casselbrant, M., Diven, W.F., et al. (1994). Sensorineural hearing loss from quinolinic acid: A neurotoxin in middle ear effusions. The Laryngoscope, 104, 176–181.
62. Young, S.N., Lal, S., Sourkes, T.L., Feldmuller, F., Aronoff, A., & Martin, J.B. (1975). Relationships between tryptophan in serum and CSF, and 5-hydroxyindoleacetic acid in CSF of man: Effect of cirrhosis of liver and probenecid administration. Journal of Neurology, Neurosurgery, and Psychiatry, 38, 322–330.
63. Zavitsanou, K., Lim, C.K., Purves-Tyson, T., Karl, T., Kassiou, M., Banister, S.D., & et al. (2014). Effect of maternal immune activation on the kynurenine pathway in preadolescent rat offspring and on MK801-induced hyperlocomotion in adulthood: Amelioration by COX-2 inhibition. Brain, Behavior, and Immunity, 41, 173–181.
64. Zimmerman, A.W., Jyonouchi, H., Comi, A.M., Connors, S.L., Milstien, S., Varsou, A., et al. (2005). Cerebrospinal fluid and serum markers of inflammation in autism. Pediatric Neurology, 33, 195–201.
65. Zufferey, F., Sherr, E.H., Beckmann, N.D., Hanson, E., Maillard, A.M., Hippolyte, L., et al. (2012). A 600 kb deletion syndrome at 16p11.2 leads to energy imbalance and neuropsychiatric disorders. Journal of Medical Genetics,. 49, 660–668.